Scholarlink

Background <p>Male pattern baldness (MPB) is commonly associated with prostate diseases, both of which can significantly impact men’s quality of life. However, the relationship and causality between them remain unclear. In this study, we investigated the causal relationship between the two.</p> Methods <p>Inverse variance weighting (IVW) was the primary Mendelian randomization method, with MR Egger, weighted median, and MRPRESSO as complements. Sensitivity analyses included Cochran’s Q, MR Egger intercept, and MRPRESSO.</p> Results <p>MPB was found to be negatively correlated with prostate cancer (IVW: OR = 0.986, 95% CI = 0.974–0.999, <i>P</i> = 0.033). This causal relationship was further supported by the weighted median (OR = 0.981, 95% CI = 0.969–0.993, <i>P</i> = 0.002), MR-Egger (OR = 0.977, 95% CI = 0.960–0.994, <i>P</i> = 0.010), and MRPRESSO (OR = 0.986, 95% CI = 0.974–0.999, <i>P</i> = 0.037) methods. Additionally, the weighted median analysis indicated that MPB was positively correlated with benign prostatic hyperplasia (BPH) (OR = 1.027, 95% CI = 1.003–1.052, <i>P</i> = 0.024).</p> Conclusions <p>Our findings suggest that genetically predicted MPB may reduce prostate cancer risk but increase the risk of benign prostatic hyperplasia. Timely prostate screening in patients with MPB could help prevent and manage prostate diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Insights of prostate diseases risk among patients with male pattern baldness: a mendelian randomized study

  • 期刊论文

  • 发表日期：

    2025年1月6日

查看全文
  • Zhiqiang Wang,
  • Zhuocheng Bao,
  • Xinfang Cao,
  • Zhinan Jing,
  • Xueli Yan,
  • Wenhua Zhao,
  • Jianmin Tian,
  • Hongyu Zhang,
  • Xue Zhao,
  • Yongan Zhou

摘要

Background

Male pattern baldness (MPB) is commonly associated with prostate diseases, both of which can significantly impact men’s quality of life. However, the relationship and causality between them remain unclear. In this study, we investigated the causal relationship between the two.

Methods

Inverse variance weighting (IVW) was the primary Mendelian randomization method, with MR Egger, weighted median, and MRPRESSO as complements. Sensitivity analyses included Cochran’s Q, MR Egger intercept, and MRPRESSO.

Results

MPB was found to be negatively correlated with prostate cancer (IVW: OR = 0.986, 95% CI = 0.974–0.999, P = 0.033). This causal relationship was further supported by the weighted median (OR = 0.981, 95% CI = 0.969–0.993, P = 0.002), MR-Egger (OR = 0.977, 95% CI = 0.960–0.994, P = 0.010), and MRPRESSO (OR = 0.986, 95% CI = 0.974–0.999, P = 0.037) methods. Additionally, the weighted median analysis indicated that MPB was positively correlated with benign prostatic hyperplasia (BPH) (OR = 1.027, 95% CI = 1.003–1.052, P = 0.024).

Conclusions

Our findings suggest that genetically predicted MPB may reduce prostate cancer risk but increase the risk of benign prostatic hyperplasia. Timely prostate screening in patients with MPB could help prevent and manage prostate diseases.